CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer
Open Access
- 15 September 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (9) , e0137397
Abstract
The cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC). We investigated CDKN3 mRNA as a survival biomarker and potential therapeutic target for CC. CDKN3 mRNA was measured in 134 CC and 25 controls by quantitative PCR. A 5-year survival study was conducted in 121 of these CC patients. Furthermore, CDKN3-specific siRNAs were used to investigate whether CDKN3 is involved in proliferation, migration, and invasion in CC-derived cell lines (SiHa, CaSki, HeLa). CDKN3 mRNA was on average 6.4-fold higher in tumors than in controls (p = 8 x 10−6, Mann-Whitney). A total of 68.2% of CC patients over expressing CDKN3 gene (fold change ≥ 17) died within two years of diagnosis, independent of the clinical stage and HPV type (Hazard Ratio = 5.0, 95% CI: 2.5–10, p = 3.3 x 10−6, Cox proportional-hazards regression). In contrast, only 19.2% of the patients with lower CDKN3 expression died in the same period. In vitro inactivation of CDKN3 decreased cell proliferation on average 67%, although it had no effect on cell migration and invasion. CDKN3 mRNA may be a good survival biomarker and potential therapeutic target in CC.Keywords
This publication has 62 references indexed in Scilit:
- A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancerBritish Journal of Cancer, 2013
- Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancerDiagnostic Pathology, 2013
- Metastasis of Neuroendocrine Tumors Are Characterized by Increased Cell Proliferation and Reduced Expression of the ATM GenePLOS ONE, 2012
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Biomarkers of Cervical Dysplasia and CarcinomaJournal of Oncology, 2011
- Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perilsEMBO Molecular Medicine, 2011
- Human Papillomavirus Testing in the Prevention of Cervical CancerJNCI: Journal of the National Cancer Institute, 2011
- MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patientsBMC Medical Genomics, 2010
- Targeting the cancer kinome through polypharmacologyNature Reviews Cancer, 2010
- A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital LesionsCancer Prevention Research, 2009